Galectin-3 secreted by triple-negative breast cancer cells regulates T cell function.

ABSTRACT: Triple-negative breast cancer (TNBC) is an aggressive subtype that accounts for 10-15 % of breast cancer. Current treatment of high-risk early-stage TNBC includes neoadjuvant chemo-immune therapy. However, the substantial variation in immune response prompts an urgent need for new immune-targeting agents. This requires a comprehensive understanding of TNBC's tumor microenvironment. We recently demonstrated that Galectin-3 (Gal-3) binding protein/Gal-3 complex secreted by TNBC cells induces immunosuppression, through inhibiting CD45 signaling in T cells. Here, we further investigated the interaction between secreted Gal-3 and T cells in TNBC. Using CRISPR/Cas9 gene editing of the TNBC MDA-MB-231 cell-line, we obtained Gal-3 negative^(neg) clones. We studied these in an in-vitro mo

SUBMITTER: Raiter A 

PROVIDER: S-EPMC11742317 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature